Effects of rapamycin on cardiac and skeletal muscle contraction and crossbridge cycling

Journal of Pharmacology and Experimental Therapeutics

Volumn 312, Issue 1, 2005, Pages 12-18

  Schoffstall, Brenda ^a   Kataoka, Aya ^a   Clark, Amanda ^a   Chase, P Bryant ^a  

^a FLORIDA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CALCIUM ION; R 5000; RAPAMYCIN;

ACTIN FILAMENT; ACTIN MYOSIN INTERACTION; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HEART CONTRACTION; HEART MUSCLE; MALE; MUSCLE CONTRACTILITY; MUSCLE CONTRACTION; MUSCLE FIBER CONTRACTION; MUSCLE HYPERTROPHY; MUSCLE ISOMETRIC CONTRACTION; MUSCLE TONE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PSOAS MUSCLE; RABBIT; RAT;

NASA DISCIPLINE MUSCULOSKELETAL; NON-NASA CENTER;

ACTOMYOSIN; ANIMALS; ANTI-BACTERIAL AGENTS; CALCIUM; HEART; ISOMETRIC CONTRACTION; KINETICS; MALE; MUSCLE CONTRACTION; MUSCLE, SKELETAL; RABBITS; RATS; SIROLIMUS;

EID: 11844254467     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.073445     Document Type: Article

References (40)

1. Boluyt MO, Zheng JS, Younes A, Long X, O'Neill L, Silverman H, Lakatta EG, and Crow MT (1997) Rapamycin inhibits α 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes: evidence for involvement of p70 S6 kinase. Circ Res 81:176-186.
2. Bonne G, Carrier L, Richard P, Hainque B, and Schwartz K (1998) Familial hypertrophic cardiomyopathy: from mutations to functional defects. Circ Res 83:580-593.
3. Bottinelli R and Reggiani C (2000) Human skeletal muscle fibres: molecular and functional diversity. Prog Biophys Mol Biol 73:195-262.
4. Brenner B (1983) Technique for stabilizing the striation pattern in maximally calcium-activated skinned rabbit psoas fibers. Biophys J 41:99-102.
5. Castro C, Campistol JM, Sancho D, Sanchez-Madrid F, Casals E, and Andres V (2004) Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1-independent pathway. Atherosclerosis 172:31-38.
6. Chase PB, Chen Y, Kulin KL, and Daniel TL (2000) Viscosity and solute dependence of F-actin translocation by rabbit skeletal heavy meromyosin. Am J Physiol Cell Physiol 278:C1088-C1098.
7. Chase PB and Kushmerick MJ (1988) Effects of pH on contraction of rabbit fast and slow skeletal muscle fibers. Biophys J 53:935-946.
8. 2+. Biophys J 67:1994-2001.
9. Chou MM and Blenis J (1995) The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signalling. Curr Opin Cell Biol 7:806-814.
10. Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, and Thomas G (2001) Mammalian TOR: a homeostatic ATP sensor. Science (Wash DC) 294:1102-1105.
11. Fatkin D and Graham RM (2002) Molecular mechanisms of inherited cardiomyopathies. Physiol Rev 82:945-980.
12. Frey N and Olson EN (2003) Cardiac hypertrophy: the good, the bad and the ugly. Annu Rev Physiol 65:45-79.
13. Gordon AM, LaMadrid MA, Chen Y, Luo Z, and Chase PB (1997) Calcium regulation of skeletal muscle thin filament motility in vitro. Biophys J 72:1295-1307.
14. 2+ on force redevelopment kinetics in skinned rat myocardium. Biophys J 70:2819-2829.
15. Homsher E, Lee DM, Morris C, Pavlov D, and Tobacman LS (2000) Regulation of force and unloaded sliding speed in single thin filaments: effects of regulatory proteins and calcium. J Physiol 524:233-243.
16. Kataoka A, Schoffstall B, Clark A, and Chase PB (2004) Effect of rapamycin on skinned skeletal muscle fiber force. Biophys J 86:213a.
17. Köhler J, Chen Y, Brenner B, Gordon AM, Kraft T, Martyn DA, Regnier M, Rivera AJ, Wang C-K, and Chase PB (2003) Familial hypertrophic cardiomyopathy mutations in troponin I (K183Δ, G203S, K206Q) enhance filament sliding. Physiol Genomics 14:117-128.
18. Kron SJ, Toyoshima YY, Uyeda TQ, and Spudich JA (1991) Assays for actin sliding movement over myosin-coated surfaces. Methods Enzymol 196:399-416.
19. Landesberg A and Sideman S (1994) Coupling calcium binding to troponin C and cross-bridge cycling in skinned cardiac cells. Am J Physiol Heart Circ Physiol 266:H1260-H1271.
20. Lin D, Bobkova A, Homsher E, and Tobacman LS (1996) Altered cardiac troponin T in vitro function in the presence of a mutation implicated in familial hypertrophic cardiomyopathy. J Clin Investig 97:2842-2848.
21. Marks AR (1996) Cellular functions of immunophilins. Physiol Rev 76:631-649.
22. Martyn DA and Gordon AM (1988) Length and myofilament spacing-dependent changes in calcium sensitivity of skeletal fibres: effects of pH and ionic strength. J Muscle Res Cell Motil 9:428-445.
23. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T, and Izumo S (2004) Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 109:3050-3055.
24. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Kang PM, and Izumo S (2003) Phosphoinositide 3-kinase(p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA 100:12355-12360.
25. Pyle WG and Solaro RJ (2004) At the crossroads of myocardial signaling: the role of Z-discs in intracellular signaling and cardiac function. Circ Res 94:296-305.
26. 2+ regulation of tension redevelopment rate in skinned skeletal muscle. Biophys J 71:2786-2794.
27. Regnier M, Martyn DA, and Chase PB (1998) Calcium regulation of tension redevelopment kinetics with 2-deoxy-ATP or low [ATP] in rabbit skeletal muscle. Biophys J 74:2005-2015.
28. 2+ relations. J Physiol 540:485-497.
29. Regnier M, Rivera AJ, Chen Y, and Chase PB (2000) 2-deoxy-ATP enhances contractility of rat cardiac muscle. Circ Res 86:1211-1217.
30. Sadoshima J and Izumo S (1995) Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro: potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Circ Res 77:1040-1052.
31. Schmelzle T and Hall MN (2000) TOR, a central controller of cell growth. Cell 103:253-262.
32. Sellers JR, Cuda G, Wang F, and Homsher E (1993) Myosin-specific adaptations of the motility assay. Methods Cell Biol 39:23-49.
33. Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ, and Izumo S (2003) Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 107:1664-1670.
34. i differ in mouse and rabbit ventricular myocytes. J Pharmacol Exp Ther 304:334-341.
35. Sweeney HL, Feng HS, Yang Z, and Watkins H (1998) Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function. Proc Natl Acad Sci USA 95:14406-14410.
36. Takahashi-Yanaga F, Morimoto S, Harada K, Minakami R, Shiraishi F, Ohta M, Lu QW, Sasaguri T, and Ohtsuki I (2001) Functional consequences of the mutations in human cardiac troponin I gene found in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol 33:2095-2107.
37. Thomas G and Hall MN (1997) TOR signalling and control of cell growth. Curr Opin Cell Biol 9:782-787.
38. 2+ sensitivity of regulated actin filament sliding by calmidazolium or α-tropomyosin mutant E180G. Biophys J 86:393a.
39. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, and Molkentin JD (2004) Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 94:110-118.
40. Woods TC and Marks AR (2004) Drug-eluting stents. Annu Rev Med 55:169-178.